Dashboard
Manage Tickers

GLPGGALAPAGOS NV

Nasdaq glpg.com


$ 29.01 $ -0.05 (-0.17 %)    

Wednesday, 08-May-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 29.03
$ 28.98
$ 0.00 x 0
$ 0.00 x 0
$ 28.94 - $ 29.06
$ 28.30 - $ 45.21
70,830
na
1.91B
$ 0.83
$ 8.17
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

galapagos-q1-eps-140-vs-040-yoy-revenue-624-million-vs-586-million-yoy
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Reven...
05/02/2024 20:37:56

Results from our continuing operationsTotal operating loss from continuing operations for the three months ended 31 March 2024 ...

morgan-stanley-maintains-equal-weight-on-galapagos-maintains-38-price-target
Morgan Stanley Maintains Equal-Weight on G...
04/22/2024 17:23:34

Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.

galapagos-plans-clinical-and-translational-data-presentations-at-ebmt-congress-2024
Galapagos Plans Clinical And Translational...
04/04/2024 20:03:43

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL...

galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress-analyst
Galapagos Downgraded, Pharma Firm Faces Up...
04/01/2024 18:37:03

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded m...

b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31
B of A Securities Downgrades Galapagos to ...
04/01/2024 11:07:37

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31
B of A Securities Downgrades Galapagos to ...
03/28/2024 10:20:03

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

morgan-stanley-assumes-galapagos-at-equal-weight-announces-price-target-of-38
Morgan Stanley Assumes Galapagos at Equal-...
03/07/2024 09:20:00

Morgan Stanley analyst Judah Frommer assumes Galapagos (NASDAQ:GLPG) with a Equal-Weight rating and announces Price Target o...

galapagos-expects-fy24-further-reduction-in-cash-burn-and-expect-cash-burn-to-be-280m-320m
Galapagos Expects FY24 Further Reduction I...
02/22/2024 21:12:43

galapgos-fy23-eps-321-up-from-332-yoy-revenue-7835m
Galapgos FY23 EPS €3.21 Up From €(3.32) Yo...
02/22/2024 21:08:06

earnings-scheduled-for-february-22-2024
Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

galapagos-to-present-new-preliminary-translational-data-and-previously-disclosed-data-from-euplagia-1-phase-12-study-at-the-european-society-for-blood-and-marrow-transplantation---8k
Galapagos To Present New Preliminary Trans...
02/16/2024 11:10:01

The preliminary translational data demonstrate that Galapagos’ differentiated point-of-care manufacturing platform offers the p...

Core News & Articles
Galapagos Enters Strategic Collaboration D...
01/04/2024 21:08:02

european-drugmaker-galapagos-collaborates-with-biotech-bridgene-biosciences-to-develop-cancer-treatments
European Drugmaker Galapagos Collaborates ...
01/03/2024 21:01:44

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...

bridgene-says-galapagos-will-pay-up-to-27m-in-upfront-and-preclinical-research-milestone-payments-more-than-700m-in-clinical-and-commercial-milestones-eligible-to-receive-tiered-royalties-on-net-sales-of-each-product-resulting-from-the-collaboration
BridGene Says "Galapagos Will Pay Up To $2...
01/03/2024 21:01:02

bridgene-biosciences-announces-strategic-collaboration-with-galapagos-to-discover-small-molecule-drugs-for-oncology-targets
BridGene Biosciences Announces Strategic C...
01/03/2024 21:00:54

b-of-a-securities-maintains-neutral-on-galapagos-raises-price-target-to-44
B of A Securities Maintains Neutral on Gal...
01/02/2024 16:03:48

B of A Securities analyst Jason Gerberry maintains Galapagos (NASDAQ:GLPG) with a Neutral and raises the price target from $...

galapagos-transforms-into-biotech-innovator-sells-jyseleca-business-to-alfasigma-with-key-executive-transition
Galapagos Transforms Into Biotech Innovato...
01/02/2024 06:22:38

In connection with the transaction, Galapagos expects to realize substantial savings ranging between €150 million and €200 mill...

galapagos-nv-announced-that-the-first-patient-has-been-dosed-in-papilio-1-the-phase-12-study-to-evaluate-the-safety-efficacy-and-feasibility-of-glpg5301-in-adult-patients-with-relapsedrefractory-multiple-myeloma
Galapagos NV Announced That The First Pati...
12/19/2023 21:03:32

GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate, administe...

galapagos-to-present-new-data-at-ash-2023-from-ongoing-cd19-car-t-studies-with-glpg5201-and-glpg5101
Galapagos To Present New Data At Ash 2023 ...
12/09/2023 20:13:31

Galapagos NV ((Euronext &, NASDAQ:GLPG) to present additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR...

galapagos-reiterates-2023-net-jyseleca-sales-guidance-of-100m-120m-and-cash-burn-guidance-of-380m-420m
Galapagos Reiterates 2023 Net Jyseleca Sal...
11/02/2023 20:40:20

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION